Apple Analyst Predicts CAPEX Doubling and 4 Investor-Focused Insights Making Rounds

Accretive Health, Inc. (NYSE:AH): Current price $9.00

Oppenheimer believes that the most likely reason for the delay of Accretive Health’s results is that auditors have decided that the company should establish a reserve for incentive fees in light of their dispute with Fairview Health over this issue. The firm noted that the company is confident that they will recognize the full amount of revenue from their deal with Fairview, and Oppenheimer maintains an Outperform rating on Accretive.

These stocks are hitting our Profit Targets. Click here now to discover winning stocks!